Literature DB >> 26561390

Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant.

Wilbur H Chen1, Lisa A Jackson2, Kathryn M Edwards3, Wendy A Keitel4, Heather Hill5, Diana L Noah6, C Buddy Creech3, Shital M Patel4, Brian Mangal5, Karen L Kotloff1.   

Abstract

The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends those findings to 1 year after vaccination.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26561390      PMCID： PMC4711091          DOI： 10.1128/CVI.00475-15

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  11 in total

1.  Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.

Authors:  Joanne M Langley; Louise Frenette; Linda Ferguson; Dennis Riff; Eric Sheldon; George Risi; Casey Johnson; Ping Li; Richard Kenney; Bruce Innis; Louis Fries
Journal:  J Infect Dis       Date:  2010-06-01       Impact factor: 5.226

2.  Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Authors:  Isabel Leroux-Roels; François Roman; Sheron Forgus; Cathy Maes; Fien De Boever; Mamadou Dramé; Paul Gillard; Robbert van der Most; Marcelle Van Mechelen; Emmanuel Hanon; Geert Leroux-Roels
Journal:  Vaccine       Date:  2009-10-14       Impact factor: 3.641

3.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

4.  Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months.

Authors:  George Risi; Louise Frenette; Joanne M Langley; Ping Li; Dennis Riff; Eric Sheldon; David W Vaughn; Louis Fries
Journal:  Vaccine       Date:  2011-05-07       Impact factor: 3.641

5.  Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

Authors:  T Rowe; R A Abernathy; J Hu-Primmer; W W Thompson; X Lu; W Lim; K Fukuda; N J Cox; J M Katz
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

6.  Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.

Authors:  Laurent Coudeville; Fabrice Bailleux; Benjamin Riche; Françoise Megas; Philippe Andre; René Ecochard
Journal:  BMC Med Res Methodol       Date:  2010-03-08       Impact factor: 4.615

7.  Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans.

Authors:  Lance C Jennings; Arnold S Monto; Paul K S Chan; Thomas D Szucs; Karl G Nicholson
Journal:  Lancet Infect Dis       Date:  2008-10       Impact factor: 25.071

8.  Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.

Authors:  Diana L Noah; Heather Hill; David Hines; E Lucile White; Mark C Wolff
Journal:  Clin Vaccine Immunol       Date:  2009-02-18

9.  Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant.

Authors:  Wilbur H Chen; Lisa A Jackson; Kathryn M Edwards; Wendy A Keitel; Heather Hill; Diana L Noah; C Buddy Creech; Shital M Patel; Brian Mangal; Karen L Kotloff
Journal:  Open Forum Infect Dis       Date:  2014-10-08       Impact factor: 3.835

10.  Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine.

Authors:  Isabel Leroux-Roels; Roger Bernhard; Pascal Gérard; Mamadou Dramé; Emmanuel Hanon; Geert Leroux-Roels
Journal:  PLoS One       Date:  2008-02-27       Impact factor: 3.240
View more
  8 in total

Review 1.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 2.  Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine.

Authors:  Florian Krammer; Adolfo García-Sastre; Peter Palese
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

3.  A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.

Authors:  Kenta Matsuda; Stephen A Migueles; Jinghe Huang; Lyuba Bolkhovitinov; Sarah Stuccio; Trevor Griesman; Alyssa A Pullano; Byong H Kang; Elise Ishida; Matthew Zimmerman; Neena Kashyap; Kelly M Martins; Daniel Stadlbauer; Jessica Pederson; Andy Patamawenu; Nathaniel Wright; Tulley Shofner; Sean Evans; C Jason Liang; Julián Candia; Angelique Biancotto; Giovanna Fantoni; April Poole; Jon Smith; Jeff Alexander; Marc Gurwith; Florian Krammer; Mark Connors
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 4.  Reverse Genetics Approaches for the Development of Influenza Vaccines.

Authors:  Aitor Nogales; Luis Martínez-Sobrido
Journal:  Int J Mol Sci       Date:  2016-12-22       Impact factor: 5.923

5.  A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.

Authors:  Neal Van Hoeven; Christopher B Fox; Brian Granger; Tara Evers; Sharvari W Joshi; Ghislain I Nana; Sarah C Evans; Susan Lin; Hong Liang; Li Liang; Rie Nakajima; Philip L Felgner; Richard A Bowen; Nicole Marlenee; Airn Hartwig; Susan L Baldwin; Rhea N Coler; Mark Tomai; James Elvecrog; Steven G Reed; Darrick Carter
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

6.  Persistence of vaccine-induced antibodies to A/H5N1 at 30 months and 36 months after vaccination in Vietnam.

Authors:  Chien Vien Chinh; Viet Phu Quoc; Loc Huynh Tan; Duoc Nguyen Van; Thai Pham Quang; Be Le Van
Journal:  Epidemiol Health       Date:  2021-10-06

7.  The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination.

Authors:  Johannes B Goll; Aarti Jain; Travis L Jensen; Rafael Assis; Rie Nakajima; Algis Jasinskas; Lynda Coughlan; Sami R Cherikh; Casey E Gelber; S Khan; D Huw Davies; Philip Meade; Daniel Stadlbauer; Shirin Strohmeier; Florian Krammer; Wilbur H Chen; Philip L Felgner
Journal:  NPJ Vaccines       Date:  2022-08-30       Impact factor: 9.399

8.  Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.

Authors:  Joseph R Francica; Barbara J Flynn; Kathryn E Foulds; Amy T Noe; Anne P Werner; Ian N Moore; Matthew Gagne; Timothy S Johnston; Courtney Tucker; Rachel L Davis; Britta Flach; Sarah O'Connell; Shayne F Andrew; Evan Lamb; Dillon R Flebbe; Saule T Nurmukhambetova; Mitzi M Donaldson; John-Paul M Todd; Alex Lee Zhu; Caroline Atyeo; Stephanie Fischinger; Matthew J Gorman; Sally Shin; Venkata Viswanadh Edara; Katharine Floyd; Lilin Lai; Seyhan Boyoglu-Barnum; Renee Van De Wetering; Alida Tylor; Elizabeth McCarthy; Valerie Lecouturier; Sophie Ruiz; Catherine Berry; Timothy Tibbitts; Hanne Andersen; Anthony Cook; Alan Dodson; Laurent Pessaint; Alex Van Ry; Marguerite Koutsoukos; Cindy Gutzeit; I-Ting Teng; Tongqing Zhou; Dapeng Li; Barton F Haynes; Peter D Kwong; Adrian McDermott; Mark G Lewis; Tong Ming Fu; Roman Chicz; Robbert van der Most; Kizzmekia S Corbett; Mehul S Suthar; Galit Alter; Mario Roederer; Nancy J Sullivan; Daniel C Douek; Barney S Graham; Danilo Casimiro; Robert A Seder
Journal:  Sci Transl Med       Date:  2021-07-27       Impact factor: 19.319
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.